Personalised treatment of psoriasis with biologics: what is important?

Introduction Patients are the center of interest in developing personalised medicine as one drug does not fit all. Current management approaches for the treatment of psoriasis depend largely on clinical assessment. However, a more precise approach should be taken into account as psoriasis is characterized by genetic polymorphism and patients have individual variations in genes, proteins, environment, lifestyle, concomitant diseases, etc. The increasing development and success of biologic treatment for psoriasis has resulted in many patients achieving complete or almost complete skin responses. Nevertheless, only a proportion of patients achieve such outcomes to the first prescribed biologic and it may take time for patients to achieve expected results. There are many challenges when treating patients with psoriasis and trying to achieve best possible results. All this will be taken into account during the speech at the BADV congress in Kaunas, Lithuania.